PCSA
Processa Pharmaceuticals, Inc.
Overview
Processa Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $5.8M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2022Earnings2023-03-312 Q&A exchanges
- Q3 FY2022Earnings2022-11-1224 Q&A exchanges
- Q2 FY2022Earnings2022-08-149 Q&A exchanges
- Q1 FY2022Earnings2022-05-1416 Q&A exchanges
- Q4 FY2021Earnings2022-03-3015 Q&A exchanges
- Q3 FY2021Earnings2021-11-1117 Q&A exchanges
- Q2 FY2021Earnings2021-08-1214 Q&A exchanges
- Q1 FY2021Earnings2021-05-149 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs ——Rev— vs ——EODHD
- Q3 FY20252025-11-05EPS$-0.07 vs $-0.45+84.4%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.25 vs $-0.23-8.7%Rev$0 vs ——EODHD
- Q1 FY20252025-05-07EPS$-0.30 vs $-1.18+74.6%Rev$0 vs ——EODHD
- Q4 FY20242025-03-26EPS$-0.74 vs $-0.92+19.6%Rev$12.5M vs ——EODHD
- Q3 FY20242024-10-29EPS$-1.03 vs $-1.00-3.0%Rev$0 vs ——EODHD
- Q2 FY20242024-08-12EPS$-1.01 vs $-0.98-3.1%Rev$0 vs ——EODHD
- Q1 FY20242024-05-09EPS$-1.11 vs $-1.18+5.9%Rev$0 vs ——EODHD
- Q4 FY20232024-03-28EPS$-1.70 vs $-1.60-6.3%Rev$0 vs ——EODHD
- Q3 FY20232023-11-12EPS$-0.08 vs $-0.10+20.0%Rev$0 vs ——EODHD
- Q2 FY20232023-08-09EPS$-0.10 vs $-0.23+57.8%Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.18 vs $-0.28+35.7%Rev$0 vs ——EODHD
- Q4 FY20222023-03-29EPS$-0.36 vs $-0.32-12.5%Rev$0 vs ——EODHD
- Q3 FY20222022-11-07EPS$-0.37 vs $-0.34-8.8%Rev$0 vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.32 vs $-0.20-60.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.20 vs $-0.21+4.8%Rev$0 vs ——EODHD
- Q4 FY20212022-03-29EPS$-0.21 vs $-0.19-10.5%Rev$175.4K vs ——EODHD
- Q3 FY20212021-11-10EPS$-0.19 vs $-0.18-5.6%Rev$0 vs ——EODHD
- Q2 FY20212021-08-11EPS$-0.20 vs $-0.14-42.9%Rev$0 vs ——EODHD
- Q1 FY20212021-05-12EPS$-0.14 vs $-0.10-40.0%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | — | — | — | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.07 | $-0.45 | +84.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.25 | $-0.23 | -8.7% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.30 | $-1.18 | +74.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-0.74 | $-0.92 | +19.6% | $12.5M | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $-1.03 | $-1.00 | -3.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-1.01 | $-0.98 | -3.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-1.11 | $-1.18 | +5.9% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-1.70 | $-1.60 | -6.3% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.08 | $-0.10 | +20.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.10 | $-0.23 | +57.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.18 | $-0.28 | +35.7% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.36 | $-0.32 | -12.5% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.37 | $-0.34 | -8.8% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.32 | $-0.20 | -60.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.20 | $-0.21 | +4.8% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-29 | $-0.21 | $-0.19 | -10.5% | $175.4K | — | — | EODHD |
| Q3 FY2021 | 2021-11-10 | $-0.19 | $-0.18 | -5.6% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-11 | $-0.20 | $-0.14 | -42.9% | $0 | — | — | EODHD |
| Q1 FY2021 | 2021-05-12 | $-0.14 | $-0.10 | -40.0% | $0 | — | — | EODHD |
Source: EODHD. PCSA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PCSA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 8/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $2.72 | $2.73 | -0.4% | +2.0% | +4.8% |
| Q4 FY2022 | $3.03 | $3.01 | +0.8% | -4.1% | -2.9% |
| Q3 FY2022 | $2.68 | $2.89 | -7.3% | -2.3% | -4.6% |
| Q2 FY2022 | $2.92 | $2.96 | -1.3% | +6.0% | +5.8% |
| Q1 FY2021 | $2.78 | $2.80 | -0.7% | +0.6% | -1.0% |
| Q4 FY2021 | $2.73 | $3.03 | -9.9% | -0.3% | +1.4% |
| Q3 FY2021 | $3.03 | $2.96 | +2.2% | +0.3% | -2.6% |
| Q2 FY2021 | $2.80 | $2.99 | -6.5% | +4.0% | +4.2% |
| Q1 FY2020 | $2.97 | $3.16 | -6.1% | -1.3% | +0.6% |
| Q4 FY2020 | $3.10 | $3.15 | -1.7% | +4.9% | +5.0% |
Guidance change history
Sample- Q1 FY2022Maintained2022-04-15
- Q4 FY2022Suspended2022-13-15
- Q3 FY2022Lowered2022-10-15
- Q2 FY2022Maintained2022-07-15
- Q1 FY2021Maintained2021-04-15
- Q4 FY2021Lowered2021-13-15
- Q3 FY2021Maintained2021-10-15
- Q2 FY2021Lowered2021-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- George K NgCEO8 mono recorded callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance cut Q1 FY2022
- Russell SkibstedCFO8 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2022
- Sian BigoraChief Development Officer8 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • guidance suspended Q1 FY2022
- Wendy GuyChief Administrative Officer11 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q1 FY2022
- Patrick LinChief Business - Strategy Off8 mono recorded callsCurrentSample
OTHER since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2022
- David YoungPres. Research & Development11 mo8 callsCurrentSample
OTHER since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2022
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PCSA.
$ curl https://api.spokenalpha.com/v1/companies/PCSAFAQ
Frequently asked about PCSA
Where can I find Processa Pharmaceuticals, Inc.'s (PCSA) earnings call transcripts?
Spoken Alpha indexes PCSA's earnings call transcripts at https://spokenalpha.com/companies/PCSA. Each call links to attributed speakers and parsed analyst Q&A. Processa Pharmaceuticals, Inc.'s own investor relations page is at https://www.processapharmaceuticals.com/investors.
When was Processa Pharmaceuticals, Inc.'s most recent earnings call?
Processa Pharmaceuticals, Inc. (PCSA) held its most recent earnings call on 2023-03-31, covering fiscal Q4 2022.
What sector is PCSA in?
Processa Pharmaceuticals, Inc. (PCSA) operates in the Healthcare sector (Biotechnology industry).